GLOBAL LIQUID BIOPSY MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL LIQUID BIOPSY MARKET FORECAST 2019-2027

GLOBAL LIQUID BIOPSY MARKET FORECAST 2019-2027

The global liquid biopsy market is anticipated to grow at a CAGR of 21.04% between 2019 and 2027 and is expected to generate revenue of $4957.3 million by 2027. A liquid biopsy is rapidly gaining traction as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer, and transplant medicine. The important drivers increasing growth in the global liquid biopsy market are rising government initiatives and growing pervasiveness of cancer cases in the older populace. Countries such as Australia, the UK, and the US are among the few developed countries that have mandated cancer check-ups in medical facilities. The increasing older populace is one of the chief factors for increased adoption of liquid biopsy tests. Aging affects the immune structure of the body.

GLOBAL LIQUID BIOPSY MARKET FORECAST 2019-2027

Liquid Biopsy Market by (Therapeutic Application, Clinical Application, Bio maker Type, Analysis Platform, Analysis Purpose, Product, End User & Geography)

Request free sample

The global liquid biopsy market is anticipated to grow at a CAGR of 21.04% between 2019 and 2027 and is expected to generate revenue of $4957.3 million by 2027. A liquid biopsy is rapidly gaining traction as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer, and transplant medicine.

The following factors primarily drive the global liquid biopsy market:

  • Rising potential of the liquid biopsy
  • Growing pervasiveness of cancer cases in the older populace
  • Growth of precision medicine
  • Growing number of diagnostic centers
  • Rising government initiatives
  • Emergence of tissue/tumor-agnostic drugs

To know more about this report, request a free sample copy.

The important drivers increasing growth in the global liquid biopsy market are rising government initiatives and growing pervasiveness of cancer cases in the older populace. Countries such as Australia, the UK, and the US are among the few developed countries that have mandated cancer check-ups in medical facilities. The increasing older populace is one of the chief factors for increased adoption of liquid biopsy tests. Aging affects the immune structure of the body.

The therapeutic application, clinical application, biomarker type, and analysis platform of liquid biopsy market are significant segmentation of the global liquid biopsy market. Liquid biopsy plays a vital role in the treatment of lung cancer. To date, the tissue biopsy is the only method opted for the diagnosis and monitoring of breast cancer. Prostate cancer is the most common cancer among men. Melanoma is usually diagnosed through a biopsy of the concerning skin lesion. Monitoring involves regular go through treatment history, physical examination, and laboratory monitoring. Prognosis of the disease helps in understanding the chances of the reoccurrence of the disease by monitoring it after the treatment. The liquid biopsy techniques allow the physicians to understand the critical nature of the disease after the diagnosis and screening procedure. The main biomarker types used in liquid biopsy include circulating cell-free nucleic acids (cfNAs). Extracellular vesicles are a varied class of lipid-bound elements shed by any cell in the body in pathological and physiological conditions. Microarray technology has been widely used in cancer research for more than a decade. Droplet Digital PCR (ddPCR) allows for the detection of target sequences that are present in the very low background against other sequences present at high concentrations. Proteomics platforms include Mass Spectrometry (MS) and biochips (lab-on-a-chip, planar arrays, and bead-based arrays).

Lack of consensus on Standard Operating Procedures (Sops) and poor compensation structures are some of the major factors hindering the global liquid biopsy market. The reimbursement and treatment monitoring for liquid biopsy is limited, and it is performed in a few laboratories. The poor reimbursement system is a significant restraint which restricts the individuals to go for cancer detection tests and affects cancer biomarkers market negatively.

The global liquid biopsy market segments include therapeutic application, clinical application, biomarker type, analysis platform, analysis purpose, products, and end-user.

Therapeutic Application is sub-segmented into:

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma Cancer
  • Other Types of Cancer
  • Non-Oncology Application

Clinical Application is sub-segmented into:

  • Treatment Monitoring
  • Prognosis and Reoccurrence Monitoring
  • Treatment Selection
  • Diagnosis and Screening

Analysis Platform is sub-segmented into:

  • NGS
  • Microarray
  • PCR
  • Proteomics
  • Other Analysis Platform

Analysis Purpose is sub-segmented into:

  • Therapy guidance
  • Diagnosis
  • Early detection/screening
  • Monitoring

Biomarker Type is sub-segmented into:

  • Nucleic Acids
  • Proteins
  • Extracellular Vesicles
  • Cells

Product is sub-segmented into:

  • Circulating Tumor DNA (cTDNA)
  • Circulating Tumor Cells (CTCs)
  • Cell-Free DNA (cfDNA)
  • Extracellular vesicles and others

End-User is sub-segmented into:

  • Physician’ office laboratories
  • Hospitals
  • Clinical diagnostic laboratories

This report covers the present market conditions and the growth prospects of the global liquid biopsy market for 2019-2027 and considered the revenue generated through the sales of liquid biopsy for therapeutic application, clinical application, biomarker type, analysis platform, analysis purpose, products, and end-user to calculate the market size by considering 2017 as the base year.

Geographically, the global liquid biopsy market has been segmented on the basis of four major regions, which include:

  • North America: The United States and Canada
  • Asia-Pacific: Japan, China, India, Japan, Australia & Rest of APAC
  • Europe: The United Kingdom, France, Germany, Italy, Spain, Russia & Rest of Europe
  • Rest of World: Latin America & Middle East and Africa

The liquid biopsy market in North America is expected to hold the largest share by 2027 possibilities owing to the increasing number of cancer cases, the demand for liquid biopsy will increase. North America holds a market share of approx. 51% in 2018. The rising incidence of cancer cases, coupled with a hike in healthcare expenditure by governments in the region, will play a significant role in driving the demand for liquid biopsy solutions in North America during the forecast period. The US and Canada have superior biopsy technologies specializing in the detection of diseases at early stages, which can significantly reduce the mortality rates of these countries.

On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the liquid biopsy market. The liquid biopsy market in APAC is witnessing the fastest growth. There is a possibility of major vendors in the market shifting their manufacturing, sales, and distribution facilities to APAC to leverage on the attractive proposition of lower cost of land and material, easily available labor, and access to a large patient market.

The liquid biopsy market is segmented based on analysis purpose, which is sub-divided into Therapy guidance, early detection/screening, monitoring, and diagnosis. On the basis of products is sub-divided into Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), and Extracellular vesicles. Further, on the basis of End-user, it is sub-divided into Physicians’ office laboratories, Hospitals, and Clinical diagnostic laboratories. The number of patient visits to physicians’ office laboratories is increasing. Large multispecialty hospitals and hospital groups that work under government sponsorship or through private entities are the key end-users, which profoundly influence market growth. Monitoring diagnostics are used to assess cancer’s aggressiveness or recurrence. The detection process of the ctDNA initially includes the collection of the blood samples from the person to be diagnosed. The real-time liquid biopsy through CTCs analysis initially includes the collection of peripheral blood samples from the patient who is to be diagnosed. The liquid biopsy tests are mostly non-invasive tests for the diagnosis and assessing of cancer, which is based on the analysis of cfDNA present in the blood plasma.

The major market companies in the global liquid biopsy market are:

  • Agilent Technologies, Inc.
  • Fischer Medical Technologies LLC
  • Boston Scientific Corporation
  • Ad-Tech Medical Instrument Corp
  • Cintec Medical Ltd.

Company Profiles covers an analysis of important players.

Agilent Technologies, Inc. is the USA-based company, headquartered in Santa Clara, California. The company was established in 1999. The company offers services, software, reagents, instruments, and consumables to applied chemical, life sciences, and diagnostics markets. Fischer Medical Technologies LLC (Fischer Medical) is a medical device manufacturing company that designs and sells medical systems for the healthcare sectors. The company provides products for use in breast imaging, breast biopsy, and electrophysiology stimulation.

Key findings of the global liquid biopsy market are:

  • Lung cancer is the majorly used therapeutic application
  • Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are the key products for liquid biopsy tests
  • Treatment monitoring is a widely used clinical application
  • PCR is the fastest-growing analysis platform
  • Early detection/screening analysis purpose constitutes the largest share in the market
  • Clinical diagnostic laboratories are the fastest-growing end-user during the forecast period
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • LUNG CANCER IS THE MAJORLY USED THERAPEUTIC APPLICATION
      • CELL-FREE DNA (CFDNA) AND CIRCULATING TUMOR DNA (CTDNA) ARE THE KEY PRODUCTS FOR LIQUID BIOPSY TESTS
      • TREATMENT MONITORING IS THE WIDELY USED CLINICAL APPLICATION
      • PCR IS THE FASTEST GROWING ANALYSIS PLATFORM
      • EARLY DETECTION/SCREENING ANALYSIS PURPOSE CONSTITUTES THE LARGEST SHARE IN THE MARKET
      • CLINICAL DIAGNOSTIC LABORATORIES ARE THE FASTEST GROWING END-USER DURING THE FORECAST PERIOD
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVERS
      • RISING GOVERNMENT INITIATIVES
      • GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
      • GROWING NUMBER OF DIAGNOSTIC CENTERS
      • GROWTH OF PRECISION MEDICINE
      • EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
      • RISING POTENTIAL OF THE LIQUID BIOPSY
    • MARKET RESTRAINTS
      • LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
      • POOR COMPENSATION STRUCTURES
      • HIGH COST OF THE TEST
    • MARKET OPPORTUNITIES
      • TECHNOLOGICAL ADVANCEMENT
      • GROWING NUMBER OF CANCER PATIENTS
      • EXPANSION IN THE EMERGING ECONOMIES
    • MARKET CHALLENGES
      • LACK OF REIMBURSEMENT
      • LACK OF SKILLED PROFESSIONALS
  1. MARKET BY THERAPEUTIC APPLICATION
    • LUNG CANCER
    • BREAST CANCER
    • PROSTATE CANCER
    • COLORECTAL CANCER
    • MELANOMA CANCER
    • OTHER TYPES OF CANCER
    • NON-ONCOLOGY APPLICATION
  2. MARKET BY CLINICAL APPLICATION
    • TREATMENT MONITORING
    • PROGNOSIS AND REOCCURRENCE MONITORING
    • TREATMENT SELECTION
    • DIAGNOSIS AND SCREENING
  3. MARKET BY BIOMARKER TYPE
    • NUCLEIC ACIDS
    • PROTEINS
    • EXTRACELLULAR VESICLES
    • CELLS
  4. MARKET BY ANALYSIS PLATFORM
    • NGS
    • MICROARRAY
    • PCR
    • PROTEOMICS
    • OTHER ANALYSIS PLATFORM
  5. MARKET BY ANALYSIS PURPOSE
    • EARLY DETECTION/SCREENING
    • THERAPY GUIDANCE
    • MONITORING
    • DIAGNOSIS
  6. MARKET BY PRODUCT
    • CIRCULATING TUMOR DNA (CTDNA)
    • CIRCULATING TUMOR CELLS (CTCS)
    • CELL-FREE DNA (CFDNA)
    • EXTRACELLULAR VESICLES AND OTHERS
  7. MARKET BY END-USER
    • PHYSICIANS’ OFFICE LABORATORIES
    • HOSPITALS
    • CLINICAL DIAGNOSTIC LABORATORIES
  8. KEY ANALYTICS
    • PORTER’S FIVE FORCES MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF RIVALRY
    • PATENT ANALYSIS
    • MARKET TRENDS
      • NEW PLAYERS APPROACH VENTURE CAPITALISTS TO ENTER INTO NICHE MARKETS
      • DIRECT-TO-CONSUMER TESTING
    • KEY LIQUID BIOPSY INITIATIVES
    • REGULATORY FRAMEWORK
    • OPPORTUNITY MATRIX
  9. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • RUSSIA
      • REST OF EUROPE
    • ASIA PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • MIDDLE EAST AND AFRICA (MEA)
      • LATIN AMERICA
  1. COMPANY PROFILES
    • AD-TECH MEDICAL INSTRUMENT CORP
    • AGILENT TECHNOLOGIES, INC.
    • ARGON MEDICAL DEVICES INC.
    • BRAUN MELSUNGEN AG
    • BECTON, DICKINSON
    • BOSTON SCIENTIFIC CORPORATION
    • BIO-RAD LABORATORIES, INC.
    • R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON, AND COMPANY)
    • CINTEC MEDICAL LTD.
    • COOK MEDICAL INC.
    • FISCHER MEDICAL TECHNOLOGIES LLC
    • M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
    • PLANMECA OY
    • ROCHE DIAGNOSTICS CORPORATION
    • QIAGEN N.V.

TABLE LIST

TABLE 1        GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 2        LIQUID BIOPSY BIOMARKER CLASSES

TABLE 3        GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES

TABLE 4        GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, 2019-2027 ($ MILLION)

TABLE 5        GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2027 ($ MILLION)

TABLE 6        GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, 2019-2027 ($ MILLION)

TABLE 7        CELL DIFFERENTIATORS

TABLE 8        GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, 2019-2027 ($ MILLION)

TABLE 9        NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES

TABLE 10      ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS

TABLE 11      DROPLET DIGITAL PCR INDUSTRY

TABLE 12      GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, 2019-2027 ($ MILLION)

TABLE 13      GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, 2019-2027 ($ MILLION)

TABLE 14      GLOBAL LIQUID BIOPSY MARKET, BY END-USER, 2019-2027 ($ MILLION)

TABLE 15      CTC-RELATED PATENTS

TABLE 16      CELL-FREE DNA-RELATED PATENTS

TABLE 17      GLOBAL LIQUID BIOPSY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 18      NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 19      EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 20      ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 21      REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, 2019-2027 ($ MILLION)

FIGURE LIST

FIGURE 1      GLOBAL LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 2      RURAL POPULATION IN DEVELOPING COUNTRIES 2017 (%)

FIGURE 3      GLOBAL LIQUID BIOPSY MARKET SHARE, BY THERAPEUTIC APPLICATION, 2018 & 2027 (%)

FIGURE 4      GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2019-2027 ($ MILLION)

FIGURE 5      TYPES OF BREAST CANCER

FIGURE 6      GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2019-2027 ($ MILLION)

FIGURE 7      GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2019-2027 ($ MILLION)

FIGURE 10   GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2019-2027 ($ MILLION)

FIGURE 11   GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2019-2027 ($ MILLION)

FIGURE 12   GLOBAL LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2018 & 2027 (%)

FIGURE 13   GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2019-2027 ($ MILLION)

FIGURE 14   GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2019-2027 ($ MILLION)

FIGURE 15   GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2019-2027 ($ MILLION)

FIGURE 16   GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2019-2027 ($ MILLION)

FIGURE 17   GLOBAL LIQUID BIOPSY MARKET SHARE, BY BIOMARKER TYPE, 2018 & 2027 (%)

FIGURE 18   GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACIDS, 2019-2027 ($ MILLION)

FIGURE 19   GLOBAL LIQUID BIOPSY MARKET, BY PROTEINS, 2019-2027 ($ MILLION)

FIGURE 20   GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2019-2027 ($ MILLION)

FIGURE 21   GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2019-2027 ($ MILLION)

FIGURE 22   GLOBAL LIQUID BIOPSY MARKET SHARE, BY ANALYSIS PLATFORM, 2018 & 2027 (%)

FIGURE 23   GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2019-2027 ($ MILLION)

FIGURE 24   GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2019-2027 ($ MILLION)

FIGURE 25   GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2019-2027 ($ MILLION)

FIGURE 26   GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2019-2027 ($ MILLION)

FIGURE 27   GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORM, 2019-2027 ($ MILLION)

FIGURE 28   GLOBAL LIQUID BIOPSY MARKET SHARE, BY ANALYSIS PURPOSE, 2018 & 2027 (%)

FIGURE 29   GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2019-2027 ($ MILLION)

FIGURE 30   GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2019-2027 ($ MILLION)

FIGURE 31   GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2019-2027 ($ MILLION)

FIGURE 32   GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2019-2027 ($ MILLION)

FIGURE 33   GLOBAL LIQUID BIOPSY MARKET SHARE, BY PRODUCT, 2018 & 2027 (%)

FIGURE 34   GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2019-2027 ($ MILLION)

FIGURE 35   GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2019-2027 ($ MILLION)

FIGURE 36   GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2019-2027 ($ MILLION)

FIGURE 37   GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2019-2027 ($ MILLION)

FIGURE 38   GLOBAL LIQUID BIOPSY MARKET SHARE, BY END-USER 2018 & 2027 (%)

FIGURE 39   GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS’ OFFICE LABORATORIES, 2019-2027 ($ MILLION)

FIGURE 40   GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2019-2027 ($ MILLION)

FIGURE 41   GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2019-2027 ($ MILLION)

FIGURE 42   PORTER’S FIVE FORCE MODEL

FIGURE 43   PATENTS FILED BY ASSIGNEE 2015-2018 (%)

FIGURE 44   GLOBAL LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2018 & 2027 (%)

FIGURE 45   NORTH AMERICA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 46   THE UNITED STATES LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 47   NEW CANCER CASES AND CANCER DEATHS IN THE US 2016-2020 (PER 100,000 POPULATION)

FIGURE 48   CANADA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 49   EUROPE LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 50   THE UNITED KINGDOM LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 51   FRANCE LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 52   GERMANY LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 53   ITALY LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 54   SPAIN LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 55   RUSSIA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 56   REST OF EUROPE LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 57   ASIA PACIFIC LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 58   JAPAN LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 59   CHINA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 60   INDIA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 61   SOUTH KOREA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 62   AUSTRALIA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 63   REST OF APAC LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 64   REST OF WORLD LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 65   MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, 2019-2027 ($ MILLION)

FIGURE 66   NUMBER OF NEW CASES IN LATIN AMERICA AND THE CARIBBEAN 2018 (%)

FIGURE 67   LATIN AMERICA BIOPSY MARKET, 2019-2027 ($ MILLION)

  1. MARKET BY THERAPEUTIC APPLICATION
    • LUNG CANCER
    • BREAST CANCER
    • PROSTATE CANCER
    • COLORECTAL CANCER
    • MELANOMA CANCER
    • OTHER TYPES OF CANCER
    • NON-ONCOLOGY APPLICATION
  2. MARKET BY CLINICAL APPLICATION
    • TREATMENT MONITORING
    • PROGNOSIS AND REOCCURRENCE MONITORING
    • TREATMENT SELECTION
    • DIAGNOSIS AND SCREENING
  3. MARKET BY BIOMARKER TYPE
    • NUCLEIC ACIDS
    • PROTEINS
    • EXTRACELLULAR VESICLES
    • CELLS
  4. MARKET BY ANALYSIS PLATFORM
    • NGS
    • MICROARRAY
    • PCR
    • PROTEOMICS
    • OTHER ANALYSIS PLATFORM
  5. MARKET BY ANALYSIS PURPOSE
    • EARLY DETECTION/SCREENING
    • THERAPY GUIDANCE
    • MONITORING
    • DIAGNOSIS
  6. MARKET BY PRODUCT
    • CIRCULATING TUMOR DNA (CTDNA)
    • CIRCULATING TUMOR CELLS (CTCS)
    • CELL-FREE DNA (CFDNA)
    • EXTRACELLULAR VESICLES AND OTHERS
  7. MARKET BY END-USER
    • PHYSICIANS’ OFFICE LABORATORIES
    • HOSPITALS
    • CLINICAL DIAGNOSTIC LABORATORIES
  8. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • RUSSIA
      • REST OF EUROPE
    • ASIA PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • MIDDLE EAST AND AFRICA (MEA)
      • LATIN AMERICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now